ring finger protein 144BGenealiases: IBRDC2 · PIR2 · bA528A10.3 · p53RFP
Q-omics provides the consensus-scored RNF144B profile across patient tissues and cancer cell-line models. RNF144B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, RNF144B is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, RNF144B protein abundance shows 22,654 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ESCA, KICH, and GBM as cancer lineages where RNF144B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF144B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF144B survival associations across molecular data types. RNF144B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF144B RNA expression–survival associations across cancer types. High RNF144B expression shows unfavorable associations in LGG, but favorable associations in ESCA, KIRC, OV, LUAD and UCS. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for RNF144B RNA expression.
This table summarizes RNF144B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF144B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF144B shows lower tumor expression in KICH, LUAD, LUSC, THCA and PAAD and higher tumor expression in BLCA. The KICH box plot shows higher RNF144B RNA expression in normal versus tumor tissue (log2 FC = −2.826, t-test p < 0.001).
This table shows molecular features associated with RNF144B in patient tissues and cancer cell lines. In patient samples, RNF144B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF144B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
